AAA
MLTX icon

Affinity Asset Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Affinity Asset Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-75,000
Closed -$3.77M – 115
2024
Q1 		$3.77M Buy
75,000
+4,012
+6% +$218K 0.47% 60
2023
Q4 		$4.29M Buy
70,988
+20,988
+42% +$1.08M 0.78% 35
2023
Q3 		$2.85M Buy
+50,000
New +$2.76M 0.8% 38

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Affinity Asset Advisors's MLTX Position: Q2 2024 in Review

Affinity Asset Advisors sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 75,000 shares — an estimated $3.77M sold.

Affinity Asset Advisors first reported a position in MLTX in Q3 2023 and held it in 3 quarters. The position peaked at $4.29M in Q4 2023. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

  • Affinity Asset Advisors reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 75,000 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $3.77M.
  • Affinity Asset Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 3 quarters.
  • Affinity Asset Advisors's MoonLake Immunotherapeutics position peaked at $4.29M in Q4 2023.
  • 111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.